Skip to main content

Advertisement

ADVERTISEMENT

News

News
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
11/05/2024
Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.
Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.
Results from the phase 2 SWOG...
11/05/2024
Oncology
News
10/24/2024
According to the phase 3 AMBASSADOR trial, adjuvant pembrolizumab significantly improved disease-free survival among patients with high-risk muscle-invasive urothelial carcinoma.
According to the phase 3 AMBASSADOR trial, adjuvant pembrolizumab significantly improved disease-free survival among patients with high-risk muscle-invasive urothelial carcinoma.
According to the phase 3...
10/24/2024
Oncology

Advertisement

News
10/24/2024
According to the phase 3 NIAGARA trial, the addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival among cisplatin-eligible patients with operable, muscle-invasive...
According to the phase 3 NIAGARA trial, the addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival among cisplatin-eligible patients with operable, muscle-invasive...
According to the phase 3 NIAGARA...
10/24/2024
Oncology
News
10/23/2024
According to results from the phase 1b FORT-2 study, 600 mg of rogaratinib is preferable to 800 mg among cisplatin-ineligible patients with FGFR RNA-overexpressing locally advanced or metastatic urothelial cancer being treated with...
According to results from the phase 1b FORT-2 study, 600 mg of rogaratinib is preferable to 800 mg among cisplatin-ineligible patients with FGFR RNA-overexpressing locally advanced or metastatic urothelial cancer being treated with...
According to results from the...
10/23/2024
Oncology
Andrea Necchi, MD
Conference Coverage
10/23/2024
Andrea Necchi, MD, discusses results from the SunRISe-4 study which assessed the addition of TAR-200 to neoadjuvant cetrelimab in a cohort of patients with muscle-invasive bladder cancer who either refused or were ineligible for...
Andrea Necchi, MD, discusses results from the SunRISe-4 study which assessed the addition of TAR-200 to neoadjuvant cetrelimab in a cohort of patients with muscle-invasive bladder cancer who either refused or were ineligible for...
Andrea Necchi, MD, discusses...
10/23/2024
Oncology

Advertisement

Conference Coverage
09/15/2024
The NIAGARA trial showed that durvalumab plus neoadjuvant chemotherapy improved EFS and OS compared to neoadjuvant chemotherapy alone in patients with muscle-invasive bladder cancer.
The NIAGARA trial showed that durvalumab plus neoadjuvant chemotherapy improved EFS and OS compared to neoadjuvant chemotherapy alone in patients with muscle-invasive bladder cancer.
The NIAGARA trial showed that...
09/15/2024
Oncology
News
09/10/2024
According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...
According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...
According to results from Cohort...
09/10/2024
Oncology
News
05/22/2024

Stephanie Holland 

Stephanie Holland 
According to results from cohort B of the phase 2 KEYNOTE-057 trial, pembrolizumab monotherapy demonstrated promising activity with manageable toxicity among patients with Bacillus Calmette-Guerin–unresponsive, high-risk non-muscle invasive...
According to results from cohort B of the phase 2 KEYNOTE-057 trial, pembrolizumab monotherapy demonstrated promising activity with manageable toxicity among patients with Bacillus Calmette-Guerin–unresponsive, high-risk non-muscle invasive...
According to results from cohort...
05/22/2024
Oncology

Advertisement

FDA Approval
04/23/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Based on results from the phase...
04/23/2024
Oncology

Advertisement